# HealthpointCapital

> HealthpointCapital is a VC fund in New York backing Medical and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 7
- Last investment: Jan 2017
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/healthpointcapital
- X (Twitter): http://twitter.com/healthpointcap
- Website: http://www.healthpointcapital.com

HealthpointCapital is a VC fund in New York focused on Medical and Biotechnology. HealthpointCapital, LLC is a values-based, research-driven private equity firm that is differentiated by its focus on the musculoskeletal industry. HealthpointCapital has over $800 million of assets under management, including co-investments, resulting in 24 corporate acquisitions for HealthpointCapital's seven platform businesses. The sevenplatform companies, Alphatec Spine, Inc., BioHorizons Implant Systems, Inc., Blue Belt Technologies, Inc., China Rehabilitation Ltd., MicroDental, Inc., Nexa Orthopedics, Inc. and OrthoAccel Technologies, Inc., represent outstanding platforms in some of the key high-growth segments of the orthopedic industry: Robotics, Spine, Dental, Extremities and Emerging Markets.

## Contacts

5 contacts available for HealthpointCapital. Shizune tracks 6 team members at HealthpointCapital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/healthpointcapital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $5M–$13M |
| Series C | $12M–$15M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 29% |
| Biotechnology | 2 | 29% |
| Manufacturing | 1 | 14% |
| Medical Device | 1 | 14% |
| Developer Platform | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Funding Round | 1 | 14% |
| Private Equity | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 14% |
| United States | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| H. Carl McCall | Vice Chairman and Managing Director | 0 | https://shizune.co/investors/profile/h-carl-mccall |
| John Chopack | Managing Director | 0 | https://shizune.co/investors/profile/john-chopack |
| John H. Foster | Chairman and CEO | 0 | https://shizune.co/investors/profile/john-h-foster |
| Joseph Fitzpatrick | Chief Financial Officer | 0 | https://shizune.co/investors/profile/joseph-fitzpatrick |
| Laing Rikkers | Senior Managing Director | 0 | https://shizune.co/investors/profile/laing-rikkers |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $15M | Series C | Jan 12, 2017 |  |
| OrthoSpace | OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures.The company’s first product has the CE mark and iscurrently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion. | $7M |  | Dec 01, 2016 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12M | Series C | May 04, 2016 |  |
| OrthoSpace | OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures.The company’s first product has the CE mark and iscurrently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion. | $8M |  | May 19, 2015 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $5M | Series B | Jan 23, 2014 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12.5M | Series B | May 29, 2013 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. |  | Private Equity | Apr 30, 2012 |  |

7 of 7 investments shown.

## Co-investors
- [S3 Ventures](https://shizune.co/investors/profile/s3-ventures) — VC Fund, 5 deals together
- [Smith & Nephew](https://shizune.co/investors/profile/smith-nephew) — VC Fund, 2 deals together
- [Triventures](https://shizune.co/investors/profile/triventures) — VC Fund, 2 deals together
- [Houston Angel Network](https://shizune.co/investors/profile/houston-angel-network) — VC Fund, 1 deal together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 1 deal together
- [Piper Sandler](https://shizune.co/investors/profile/piper-jaffray) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Medical Investors in Israel](https://shizune.co/investors/medical-investors-israel)
- [Medical VC Funds in Israel](https://shizune.co/investors/medical-vc-funds-israel)
- [Medical Device Investors in Middle East](https://shizune.co/investors/medical-device-investors-middle-east)
- [Medical Device VC Funds in Middle East](https://shizune.co/investors/medical-device-vc-funds-middle-east)
- [Medical Device Investors in Israel](https://shizune.co/investors/medical-device-investors-israel)
- [Medical Device VC Funds in Israel](https://shizune.co/investors/medical-device-vc-funds-israel)

## FAQ

### What does HealthpointCapital invest in?

HealthpointCapital invests primarily in Medical, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is HealthpointCapital's check size?

HealthpointCapital typically joins rounds of $5M–$13M at Series B and $12M–$15M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HealthpointCapital participates in.

### How do I contact HealthpointCapital?

Public channels for HealthpointCapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HealthpointCapital?

The team at HealthpointCapital includes H. Carl McCall (Vice Chairman and Managing Director), John Chopack (Managing Director) and John H. Foster (Chairman and CEO), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co